Introduction
Multiple new anti-tumor agents have become available to treat men with metastatic castration resistant prostate cancer (mCRPC) including cabazitaxel, abiraterone, enzalutamide and sipuleucel-T [1] . Immunotherapy with sipuleucel-T represents the first therapeutic vaccine demonstrated to improve outcomes in an advanced malignancy and provides a rationale to continue the investigation of immunotherapy for CRPC. Despite these advances, the median survival of mCRPC is~20 months. Hence, the discovery of novel and tolerable agents remains a priority in this elderly population with generally multiple comorbidities.
Testis cancer antigens, including NY-ESO-1, are expressed in a variety of malignancies but not in normal tissues with the exception of testis [2, 3] . Additionally, NY-ESO-1 elicits humoral and cellular responses associated with anti-tumor activity [4] [5] [6] [7] . NY-ESO-1 expression ranges from 5 % to 30 % of patients with mostly localized or locally advanced prostate cancer [8] . NY-ESO-1 was recently identified as an MHC class II restricted tumor antigen [9, 10] . Sixteen of 17 melanoma patients who developed a humoral response against NY-ESO-1 were HLA-DP4-positive [11] .
Clinical and immune responses have been observed in melanoma patients treated with NY-ESO-1 peptides [12] [13] [14] [15] [16] . T cells can recognize NY-ESO-1 peptides presented by different HLA molecules, and have also been induced from peripheral blood mononuclear cells (PBMCs) of patients with prostate cancer [9-11, 17, 18] . Hence, we planned a phase I trial at the Baylor College of Medicine to primarily evaluate the feasibility and immunogenicity of tailored NY-ESO-1 class-I and/or class-II restricted peptides in men with mCRPC and corresponding HLA genotypes. We hypothesized that stimulation of T cell responses by MHC class I-and IIrestricted peptides will be safe and will enhance anti-tumor immune response. Furthermore, we aimed to identify potential differentials in signals of immunogenicity by HLA genotype and preliminary signals of antitumor activity. We also planned to employ GM-CSF (granulocyte macrophage colony stimulating factor) as an adjuvant based on clinical trials demonstrating safety and activity as a single agent and as cellular GM-CSF secreting immunotherapy [19, 20] .
Materials and methods

Patient eligibility
Patients with progressive mCRPC regardless of prior chemotherapy, Zubrod Performance Status ≤2, PSA ≥10 ng/ml and a castrate testosterone level (<50 ng/dL) were eligible. Progression was defined as symptomatic or measurable tumor progression, or PSA increase ≥50 % confirmed by repeating ≥2 weeks later. Adequate bone marrow, hepatic and renal function were required. The appropriate HLA class I (A2) and class II haplotypes (DR4, DP4) were required. Patients with central nervous system metastasis, immunosuppressive drugs intake and serious acute illness and those positive for hepatitis B surface antigen, Hepatitis C or HIV antibody were ineligible. Patients with a history of cardiac arrhythmia or ischemic heart disease were ineligible following an amendment owing to a myocardial infarction in one patient (see Feasibility and toxicities section below). The trial was approved by the BCM Institutional Review Board (IRB) and registered on clinicaltrials.gov (NCT00711334).
Synthesis of GMP grade NY-ESO-1 peptides
The most immunogenic peptides restricted by DR4, DP4 and HLA-A2 restricted NY-ESO-1 peptide were employed [11] . The peptide sequences are as follows: DR4-restricted NY-ESO-1 peptide: PGVLLKEFTVSG (ESO DR4-1P), DP4-restricted NY-ESO-1 peptide: YGRKKRRQRRRSLLMWITQAFLPV, and the A2-retricted peptide: SLLMWITQC.
Trial design and administration of therapy A phase I trial was designed with a primary endpoint of safety and a secondary endpoint of immune response. Three groups with ≥3 patients in each group received the peptides every 2 weeks for 6 doses. If class I or class II binding peptides were safe individually in patients with class I and class II genotypes respectively, subsequent patients with both HLA class I and class II types were planned to be able to receive both types of peptides in combination. Group 1 received a peptide presented by an HLA class I haplotype (HLA-A2), Group 2 was treated with a peptide binding to an HLA class II haplotype (DR4, DP4), and Group 3 received peptides presented by both Class I and II haplotypes. Logistically, if the patient was HLA-A2 positive, he was assigned to treatment group 1, regardless of the DR or DP type, until treatment group 1 accrual was complete. If group 1 filled, the HLA-A2 positive patient was enrolled in group III if positive for DR4 or DP4. If HLA-A2 was negative, and DR4 or DP4 was expressed, the patient was assigned to group 2. If one class II marker was positive, the patient received the corresponding peptide. If more than one class II marker was positive, then the peptide chosen targeted DR4 preferably, and then DP4. The decision to prefer DR4 was made arbitrarily, but was intended to have a consistent schema rather than random selection of DR4 or DP4. If grade ≥3 toxicity up to 1 month following the last dose attributable to therapy was observed in either Group I or Group II, then enrollment was held in Group III. If only one subject in a cohort experienced grade ≥3 toxicity, then the cohort was expanded by 3 patients, and the cohort terminated if grade ≥3 toxicity occurred in an additional patient. If grade ≥3 toxicity was observed in >1 patient in any group, then no further patients were enrolled into that group or Group III. If toxicity grade ≥3 occurred in 3 patients, the study was to be terminated.
Group I and Group II received 1 dose of 1 mg and Group III received doses of 1 mg for each of the 2 peptides. This dose was chosen based on the activity of this dose in prior clinical studies in other malignancies and there was no dose escalation [16] . The peptides were stored at −20°C in 0.5 ml and mixed with Montanide ISA 51 prior to administration. The dose and formulation have been derived from previous clinical trials in other malignancies [16, [21] [22] [23] . The vaccine was delivered subcutaneously in the upper arm in a volume of 1 ml using standard methods of good clinical practice and the patient was observed for 1 h. Androgen-deprivation was continued. Granulocytemacrophage colony stimulating factor (GM-CSF) was to be given for 5 days, beginning 2 days before peptide administration, but the protocol was amended to remove the administration of GM-CSF due to toxicity in an initial patient (see below).
Clinical and laboratory assessments during therapy
Clinical tumor evaluation assessment was performed at baseline and at least every 12 weeks. History and physical exam were performed at baseline and at weeks 5 and 13. Complete blood cell counts, comprehensive metabolic profile, LDH, PSA and urinalysis were performed at baseline and weeks 5 and 11. Blood was drawn prior to treatment, week 5 and 11 and at post-treatment evaluation in week 13 for immune monitoring studies. The tubes were transported to the laboratory where PBMCs were isolated by FicollPaque gradient (Pharmacia AB, Uppsala, Sweden) and cryopreserved until ≥3 sequential specimens were obtained for a single experiment, thereby minimizing inter-assay variability.
Measurement of PBMCs/T-cell response to NY-ESO-1
Increased Th1 cytokine elaboration compared to baseline by the patient's PBMCs against NY-ESO-1 peptides was measured in vitro by Enzyme-linked immunosorbent spot (ELISPOT) assays. PBMCs from patients were suspended in RPMI-1640 supplemented with 10 % heat-inactivated AB serum (Valley Biomedical, Winchester, USA), 2 mM lglutamine, 100 U/ml penicillin and 100 μg/ml streptomycin. Cells were cultured in 24-well plates, and individual NY-ESO-1 peptides were added to a final concentration of 20 μg/ml per well and incubated for 7 days at 37°C, 5 % CO 2 in humidified air. Recombinant hIL-2 (Proleukin; Chiron, Emeryville, CA, USA) 300 U/ml was added on day 1. Cells were harvested on day 7, washed twice in RPMI-1640 and used for ELISPOT assay. The IFN-γ ELISPOT assay was performed as previously described to quantify peptide-specific PBMCs/T cells after in vitro expansion [24] .
Measurement of antibody response to NY-ESO-1
Antibodies to NY-ESO-1 were measured by Enzyme Linked Immunosorbent Assay (ELISA), which was performed as previously described with a slight modification [25] . A positive reaction is defined as an OD value of diluted serum that exceeds the mean OD value of sera from normal donors by 2 SD values.
Statistical considerations
Assuming that the population incidence of HLA-A2 is 50 % and 78 % of patients will be positive for HLA-DR4, -DP4, or -DR13 molecules, to enroll ≥3 patients for each of the 3 groups, 16-18 prequalified patients were planned to be screened for HLA-A2 (http://www.ashi-hla.org/publicationfiles/archives/ prepr/mori_abd.htm) [26] . The primary goal of the Phase I trial was to evaluate safety. Evaluability for toxicity required completion of the first four treatments with vaccine unless serious toxicity resulted in treatment modification before then, in which case the patient was evaluable regardless of the number of weeks of treatment. For NY-ESO-1 peptides, the sample size of 3 patients in each group assured that there was 83.4 % probability of observing at least one patient with a toxic event if the true rate of toxicity for the whole population is 45 %, and 70.3 % probability if the true rate is 33.3 %. Summary statistics were performed and implausible and missing values were identified and double-checked with laboratory personnel for accuracy. Mean differences between immune parameters prior to the first vaccination and after treatments were assessed using paired t-tests when the normality assumption was true based on the KolmogorovSmirnov test. Otherwise, the Wilcoxon signed rank test was employed. The criterion for significance (α) was 0.05. All tests were 2-tailed and analysis was conducted using SPSS version 11. The baseline and on-trial PSA-doubling time (DT) was calculated by using an online calculator (http:// nomograms.mskcc.org/Prostate/PsaDoublingTime.aspx) and by employing ≥3 PSA values over a period of 1-4 months immediately preceding and during the 12 weeks of trial therapy, respectively.
Results
Patient characteristics
Patients were enrolled between June 2006 and March 2011 in the Michael E. DeBakey Veterans Affairs Medical Center, an affiliate of Baylor College of Medicine, Houston, Texas (Table 1) . Fourteen patients received any protocol related therapy and were considered evaluable for toxicities. Three of the 14 patients received GM-CSF with 0, 2 and 5 doses of vaccine, respectively. Two other patients received 1 and 2 doses of the vaccine, respectively, without GM-CSF. Thus, 9 patients received all 6 doses without GM-CSF and were considered evaluable for efficacy, i.e. clinical and immune responses. The median PSA was 56.7 ng/ml in evaluable patients. All patients had bone metastasis and pain was present in 6 of 9 evaluable patients. Of the 9 evaluable patients, 4 were chemonaïve and 5 had received docetaxelbased chemotherapy.
Feasibility and toxicities
The protocol initially specified that GM-CSF was to be given for 5 days, beginning 2 days before the peptide administration. A fatal myocardial infarction occurred in one patient after his first dose of GM-CSF was administered but before any peptide was given. The patient had diabetes, hypertension, and multiple bony metastases. He experienced significant pain probably from the growth factor, which was considered to be a possible precipitating factor that led to his myocardial infarction. Following this event, GM-CSF was omitted from the conditioning regimen and patients with prior cardiovascular diseases were excluded from the protocol. These decisions were made based on the comments from the data safety review board since the potential risks from GM-CSF were considered to outweigh the potential benefits. The exclusion of patients with cardiac disease was predicated on the possibility that arthralgias and myalgias from the vaccine itself may potentially pose a risk.
Of the remaining 2 men who received GM-CSF with vaccine, one patient was removed from trial after 2 doses due to grade 4 anemia, and another patient was removed after 5 doses due to grade 3 syncope unlikely related to therapy. Of the 2 men who received 1 or 2 doses of the vaccine without GM-CSF, one was removed after 2 doses due to grade 2 chest pain possibly related to therapy and another patient was removed after one dose due to disease progression. After this modification in the protocol, no dose-limiting or grade ≥2 toxicities were observed that were possibly related to therapy ( Table 2) . Potential therapy related grade 1 toxicities were local injection site erythema (n=5), fatigue (n=3), flu-like symptoms (n=1), myalgias (n=1), anorexia (n=2), nausea (n=2) and leukocytosis (n=2).
Immunological response
PBMCs/T cell responses were observed against the corresponding NY-ESO-1 peptides as measured by ELISPOT assay (Fig. 1) . Peptide-specific T cells were induced in 6 out of 9 evaluable patients at any time point up to 13 weeks 9 patients received all 6 doses without GM-CSF, 3 patients received GM-CSF with 0,2 and 5 doses of vaccine, 2 patients received 1-2 doses of vaccine without GM-CSF; * 1 death from myocardial infarction occurred following GM-CSF and was considered possibly from therapy (the patient did not receive the peptide); this patient also had generalized pain and myalgias after GM-CSF injection after baseline, but were not detectable in 3 patients even after receiving 6 peptide doses (Table 3) . Increase in ELISPOT response with time was observed. Antigenspecific T cell responses were observed in patients who received peptides restricted by class I and/or class II molecules. Docetaxel-naïve patients appeared to exhibit T-cell responses more frequently (4 of 4) compared to docetaxelpretreated patients (2 of 5). Among the 6 patients with T-cell response, 3 exhibited slowing of PSA-doubling time (DT), while all 3 patients without a detectable T-cell response exhibited slowing of PSA-DT (Table 3) . NY-ESO-1 antibody was only detectable in 1 of 9 patients (this patient had received a DR4 restricted NY-ESO-1 peptide immunization) (Fig. 2) . However, the peptide immunization did not change (Fig. 2) .
Increase in PSA doubling time
The median PSA doubling time pre-therapy and during therapy were 3.1 and 4.92 months, respectively ( Table 3) . The PSA-DT was prolonged compared to baseline in 6 patients including a negative PSA slope (i.e. PSA decline) in one patient. This patient demonstrated a PSA decline of 26.9 % (4583.73→3351.41). Another patient demonstrated a minor PSA decline of 3.27 % (Fig. 3) . Three of the 6 patients with slowing of PSA doubling also demonstrated T cell response to NY-ESO-1 peptides. Slowing of PSA-DT was observed in patients who received peptides restricted by class I and/or class II molecules. In accordance with Prostate Cancer Working Group (PCWG)-2 guidelines, all of the maximum levels of PSA changes during the 12 weeks of therapy are shown in the waterfall plot (Fig. 3) [27].
Discussion
This phase I clinical trial demonstrated feasibility and potential biologic anti-tumor activity for NY-ESO-1 peptides tailored for activity in patients expressing HLA class I (A2) and/or class II (DR4, DP4) molecules in men with mCRPC. Among 9 evaluable patients who received all 6 doses of the peptides, antigen-specific T cell responses, i.e. release of IFN-γ by PBMCs in response to NY-ESO-1 exposure in vitro, were observed in 6 patients. Moreover 6 of the 9 evaluable patients exhibited slowing of PSA-DT compared to baseline, including PSA decline of 26.9 % in one patient. Fig. 2 Presence of NY-ESO-1 antibody in the prostate cancer patients. Sera were collected prior to and after vaccinations with peptides, and were diluted in 2 % BSA/PBS at 1:100. ELISA assay was used for detection of the presence of NY-ESO-1 antibody in the diluted sera. Each symbol represents a patient at baseline (week 0), week 3, week 6 or 13 after initial peptide immunization. Positive reaction is defined as an OD value of diluted serum that exceeds the mean OD value of sera from normal donors by 2 SD values Antigen-specific T cell response was observed in patients receiving peptides restricted by class I and/or class II molecules. In conjunction with this signal of biologic activity, the toxicity profile was excellent after the amendment to omit GM-CSF administration. Hence, HLA-restricted NY-ESO-1 naked peptides may warrant further evaluation as single agent or in combination regimens in patients with mCRPC. Intriguingly, docetaxel-naïve patients appeared to exhibit ELISPOT immune responses more frequently (4 of 4 patients) compared to docetaxel-pretreated patients (2 of 5 patients). No clear association of slowing of PSA-DT and immune response was observed, probably due to a small number of patients. Additionally, although baseline PSA-DT appears to be prognostic, extension of PSA-DT after therapeutic intervention has not been validated to translate to improved clinical outcomes [28] . Slowing of PSA-DT after therapy may be indicative of a biologic effect of therapy as reported in other trials [19] . Moreover, the relatively rapid baseline PSA-DT (3.1 months) may render the slowing of PSA-DT easier to identify and unlikely to be due to chance alone. Guidelines to facilitate the standardization of methodology to measure PSA-DT should be adopted rapidly to assist in its validation as an intermediate endpoint [29] .
Our trial did not formally evaluate clinical anti-tumor activity, and had predefined objectives of demonstrating feasibility and immune responses. Indeed, early evidence of clinical antitumor activity is unlikely with immunotherapeutic agents, which generally demonstrate delayed benefits. Moreover, our trial did not stipulate specific post-trial therapy, which is likely to confound the interpretation of delayed benefits in the absence of a randomized trial design. Immune related response criteria have been proposed to address different patterns of response, which may even include initial progression before a delayed response or stability [30] . The trial was underpowered to detect lower rates of toxicities. However, phase I trials are typically underpowered to detect low rates of severe toxicities and we used standard Phase I conventions. Moreover, resource constraints did not allow expansion of cohorts.
Nevertheless, a solid rationale exists for earlier application of immunotherapy to chemonaïve patients. Furthermore, in this group of 9 evaluable patients, no specific HLA restricted peptide appeared to be clearly associated with more frequent slowing of PSA-DT or immune responses. While antibody responses against NY-ESO-1 were not observed, the major anti-tumor immune response is considered to be T-cell mediated. It is noteworthy that patients enrolled in our phase I trial had relatively advanced disease. Therefore, the administration of peptides to asymptomatic or minimally symptomatic and chemonaïve disease only may have elicited more potent immune and clinical responses. Moreover, given the excellent tolerability, higher doses of peptides may warrant evaluation. Unfortunately, our trial enrolled a small number of patients and lacked the resources to investigate higher doses of peptides in a larger number of cohorts. An alternative strategy of eliciting optimal immunity may entail overcoming immune suppression in the tumor microenvironment. We are currently evaluating whether inhibiting regulatory T (Treg) cellmediated immune suppression can enhance therapeutic antitumor immunity.
We omitted GM-CSF after observing toxicities, which may have also attenuated the immunogenicity of the vaccine. The presumed mechanism of fatal myocardial infarction in a single patient is unclear. However, this unfortunate event was possibly partly from marrow expansion from GM-CSF in a patient with multiple bony metastases causing substantial pain, which led to stress and a subsequent myocardial infarction in the setting of several risk factors for coronary artery disease. Previous trials evaluating GM-CSF in trials enrolling prostate cancer patients have reported manageable mild toxicities, including fatigue, fever, injection site reactions, arthralgias, and nausea [19] . It is also recommended that GM-CSF should be used with caution in patients with preexisting cardiac disease due to a small risk of transient supraventricular arrhythmias (Leukine package insert, Bayer Healthcare Pharmaceuticals, Inc.).
Given that peptide-based immunotherapy requires a specific human leukocyte antigen (HLA) allele to enable recognition by host T lymphocytes, a strategy of administering a cocktail of peptides has been evaluated in order to account for all HLA types. A randomized phase II trial (n=57) comparing estramustine phosphate alone or with a personalized peptide derived from PSA, PAP, PSMA, multidrugresistance protein and other epithelial tumor antigens in 57 HLA-A2-positive or HLA-A24-positive mCRPC patients demonstrated an extension of PFS [31] .
While multiple immunotherapeutic modalities are emerging, naked peptide vaccines are advantageous since they appear highly tolerable, and are off the shelf products that may be prepared readily and cheaply, and can be individualized based on host HLA antigen profile. In conjunction with their clinical development, biomarkers predictive for efficacy and relevant markers for optimal immune response and intermediate clinical endpoints are urgently needed.
